Aarti Drugs Limited has received formal confirmation from its Registrar and Transfer Agent regarding the processing of securities during the fourth quarter of the financial year. The company confirmed that all dematerialisation requests received for the period ending March 31, 2026, have been processed, verified, and updated in the register of members within the prescribed timelines.
Quarterly Dematerialisation Update
Aarti Drugs Limited has concluded its compliance requirements for the quarter ended March 31, 2026. Through its Registrar and Transfer Agent, MUFG Intime India Private Limited, the company has verified that all securities received for dematerialisation were handled in accordance with established standards.
Verification and Processing Standards
The company confirmed that all security certificates received during this quarter were mutilated and cancelled following rigorous verification processes. This ensures that the records held by depositories are accurate and reflect the current registered ownership. All validated requests were successfully integrated into the company’s register of members within the required timeframe, providing seamless service to shareholders opting for electronic holdings.
Listing Status
The shares associated with these dematerialisation requests have been confirmed as listed on the stock exchanges where the company’s existing securities are traded. This update ensures continued transparency and operational efficiency for all stakeholders of Aarti Drugs Limited.
Source: BSE
